Mast Cell Activation Syndrome (MCAS) in NYC: Diagnosis, Testing, and an Integrative Treatment Plan

Mast cell activation syndrome (MCAS) is one of the most commonly missed explanations for patients who feel inflamed everywhere and diagnosed nowhere. If you flush after meals, react to foods you tolerated a year ago, get hives from heat or friction, and have been told by three specialists that your labs "look fine," mast cell overactivity deserves a serious look. At Regen Health Physicians in NYC, Dr. Ajit Dhaliwal evaluates patients with these multi-system patterns using a structured, evidence-based process rather than a symptom-by-symptom chase.

This guide explains what mast cells actually do, how MCAS differs from allergy and mastocytosis, what testing is meaningful, and how an integrative treatment plan is built and sequenced.

What Mast Cells Do — and What Happens When They Misfire

Mast cells are long-lived immune cells that sit at the body's borders: skin, gut lining, airways, and the tissue around blood vessels and nerves. They are your first-response network. When they detect a threat, they degranulate — releasing histamine, tryptase, heparin, prostaglandin D2, leukotrienes, and dozens of cytokines within seconds, then producing a second wave of mediators over hours.

That machinery is essential for wound healing and defense against parasites and venoms. The problem in MCAS is not the number of mast cells (as in mastocytosis) but their threshold. They fire too easily, to too many triggers, and they release mediators in tissues where those mediators cause symptoms rather than protection.

Why the Symptoms Are So Scattered

Because mast cells live near nerves and vessels in nearly every organ, mediator release produces symptoms that look unrelated on paper:

• Skin: flushing, hives, dermatographism (writing on skin leaves a welt), itching without a rash
• Gastrointestinal: reflux, cramping, alternating diarrhea and constipation, nausea, food reactions that shift week to week
• Cardiovascular/autonomic: racing heart on standing, blood pressure swings, lightheadedness, presyncope
• Neurologic: brain fog, headaches, temperature dysregulation, poor sleep
• Respiratory/ENT: throat tightness, nasal congestion, non-infectious sinus symptoms
• Systemic: fatigue that worsens after triggers, bone or muscle pain, chemical and fragrance sensitivity

The diagnostic clue is not any single symptom. It is two or more organ systems reacting episodically, together, to identifiable triggers.

MCAS Is Not the Same as Allergy or Mastocytosis

Patients often arrive having been "cleared" by allergy testing. That testing answers a different question.

| | Classic allergy | MCAS | Systemic mastocytosis | |---|---|---|---| | Mechanism | IgE-specific to a defined allergen | Mast cells hyper-reactive to many, often non-IgE triggers | Clonal overgrowth of abnormal mast cells | | Skin/IgE testing | Usually positive | Often negative | Variable | | Baseline tryptase | Normal | Usually normal or mildly elevated | Often persistently >20 ng/mL | | Trigger list | Narrow and reproducible | Broad and shifting (heat, exercise, alcohol, stress, scents, high-histamine foods) | Variable |

Negative allergy testing does not rule out MCAS. It rules out IgE-mediated allergy, which is only one of several ways a mast cell can be activated — others include complement, neuropeptides such as substance P, IgG, physical stimuli, hormonal shifts, and direct activation via the MRGPRX2 receptor.

Conditions That Travel With MCAS

MCAS rarely arrives alone. Recognizing the cluster changes the treatment plan:

• Dysautonomia/POTS — mediator-driven vasodilation worsens orthostatic intolerance
• Hypermobility spectrum disorders — the well-described triad with POTS and MCAS
• Histamine intolerance — reduced DAO enzyme activity amplifies dietary histamine load
• Small intestinal bacterial overgrowth and intestinal permeability — a leaky, dysbiotic gut is a continuous mast cell stimulus, which is why we address the gut in parallel (see our work on chronic disease and autoimmunity)
• Post-viral syndromes — a sizeable subset of long-COVID and post-EBV patients show mast cell features
• Chronic pain and central sensitization — mast cell mediators sensitize peripheral nerves

How MCAS Is Evaluated at Our NYC Practice

There is no single confirmatory test. Diagnosis rests on the widely used consensus framework: (1) episodic multi-system symptoms consistent with mediator release, (2) objective evidence of mediator elevation, and (3) symptom improvement on mediator-targeted therapy. Not every patient meets all three, and treatment decisions are made clinically.

Step 1: A Trigger and Timeline History

We map symptom onset against infections, surgeries, pregnancies, mold or chemical exposures, and medication changes. We also build a trigger inventory — heat, alcohol, exercise, fasting, menstrual phase, stress, NSAIDs, opioids, contrast dye, fragrance. Patterns here are often more diagnostic than any lab.

Step 2: Mediator Testing, Collected Correctly

Collection technique determines whether results mean anything. Mediators are unstable, so samples must be chilled and processed promptly, and ideally drawn during or shortly after a flare.

• Serum tryptase — baseline, plus an acute sample during a reaction if feasible. A rise of 20% above baseline plus 2 ng/mL during an episode is the accepted activation criterion.
• 24-hour urinary N-methylhistamine
• 24-hour urinary 11-beta-prostaglandin F2-alpha and leukotriene E4
• Plasma histamine (chilled, prompt centrifugation)
• Chromogranin A — interpreted with care; proton pump inhibitors falsely raise it

Step 3: Ruling Out the Mimics

Carcinoid, pheochromocytoma, thyroid disease, celiac disease, eosinophilic esophagitis, hereditary alpha-tryptasemia, and clonal mast cell disease all overlap. We also screen for iron deficiency and B12 status, which magnify fatigue and orthostatic symptoms. Persistently high tryptase warrants hematology referral to evaluate for mastocytosis.

Step 4: Assessing the Drivers

Testing that shapes the plan rather than just the label: comprehensive stool analysis for dysbiosis, evaluation for SIBO, markers of intestinal permeability, mold and mycotoxin exposure history, and hormone assessment — estrogen fluctuation is a documented mast cell trigger, which is why some women's symptoms track their cycle or perimenopause. Where indicated, we coordinate with hormone evaluation as part of the same plan.

Treatment: Stabilize First, Then Rebuild

The order matters. Aggressive gut protocols or detox programs started in an unstable patient usually cause flares. We stabilize the mast cells, then work upstream.

Phase 1: Reduce the Load (Weeks 1–4)

Trigger reduction. Remove the highest-yield triggers first: alcohol, obvious high-histamine foods (aged cheese, cured meats, fermented foods, leftovers stored more than 24 hours), fragrance exposure, and non-essential medications known to destabilize mast cells. Cooking fresh and freezing leftovers immediately reduces dietary histamine meaningfully.

A low-histamine trial — with a deadline. We use a structured 4-week trial, then systematically reintroduce. A permanently restricted diet is a treatment failure, not a treatment. Long-term restriction worsens the microbiome and nutritional status, which raises reactivity over time.

H1 and H2 blockade. Second-generation H1 antihistamines (cetirizine, fexofenadine, or loratadine) are the foundation, sometimes twice daily. An H2 blocker such as famotidine is added for gastrointestinal and flushing symptoms. Many patients need both classes, dosed steadily rather than as needed.

Phase 2: Add Stabilizers (Weeks 2–12)

• Cromolyn sodium — an oral mast cell stabilizer, started at very low doses for GI-dominant disease and titrated slowly
• Ketotifen — combined H1 antagonist and stabilizer, useful when antihistamines alone are insufficient
• Leukotriene modifiers (montelukast) — for respiratory and skin-dominant symptoms
• Aspirin or other prostaglandin-directed therapy — for flushing and headache in carefully selected patients who tolerate NSAIDs
• Quercetin, luteolin, vitamin C, and DAO enzyme support — reasonable adjuncts with plausible mechanisms; used as additions to, not replacements for, medical therapy
• Vitamin D repletion — deficiency is associated with greater mast cell reactivity

Escalation is stepwise and single-variable. Adding one agent at a time is the only way to know what actually helped.

Phase 3: Address the Upstream Drivers (Month 2 Onward)

Once symptoms are 40–60% better, we treat the reasons the mast cells were primed:

• Gut repair and microbiome work — treating SIBO or dysbiosis, restoring the mucosal barrier, gradually rebuilding dietary diversity. This is where our chronic disease program and peptide therapy options intersect; peptides studied for mucosal and tissue repair, such as BPC-157 and KPV, are considered case by case.
• Autonomic rehabilitation — hydration and sodium strategy, compression, recumbent-to-upright graded exercise for coexisting POTS
• Nervous system regulation — mast cells are directly innervated and respond to substance P and CRH. Sleep consolidation, breathwork, and stress-load reduction are mechanistic interventions here, not soft advice.
• Hormonal stabilization — for cycle-linked or perimenopausal flare patterns
• Environmental remediation — mold exposure must be removed from the environment, not merely supplemented around

Phase 4: Treating What Inflammation Left Behind

Many long-standing MCAS patients carry accumulated musculoskeletal problems — tendinopathies and joint pain from years of deconditioning, hypermobility, and inflammatory pain. Once mast cells are stable, regenerative options become appropriate. Our regenerative medicine program for joint, back, and shoulder pain and broader orthopedic services can then be applied with far less risk of a reaction to the procedure itself. We deliberately do not perform elective injections in an unstable patient.

What Recovery Realistically Looks Like

• Weeks 1–4: Flushing, hives, and reflux typically respond first. Fatigue and brain fog lag.
• Months 2–3: Reaction threshold rises — the same trigger produces a smaller response. Food reintroduction usually becomes possible.
• Months 4–6: Autonomic symptoms and exercise tolerance improve. Most patients on a structured plan report substantial functional gains by this point.
• Beyond 6 months: The goal shifts to the lowest effective medication regimen and the widest tolerable diet. Flares still happen — after infections, high-stress periods, and hormonal shifts — and are managed with a written flare plan rather than panic.

MCAS is generally a condition to be managed well, not cured outright. Managed well, though, most patients get their life back.

Emergency Preparedness

Any patient with a history of severe reactions, throat tightness, or near-syncope should carry epinephrine and have a written action plan. Anaphylaxis in MCAS can be triggered by things that seem trivial — heat, exercise, or a routine medication — and it is treated the same way as any other anaphylaxis: epinephrine first, emergency services second.

Also plan ahead for procedures. Surgical premedication protocols with antihistamines and corticosteroids, plus avoidance of known mast cell–activating anesthetics and opioids, prevent most perioperative problems. Tell every clinician you see, and bring documentation.

Frequently Asked Questions

Can normal tryptase rule out MCAS? No. Most MCAS patients have normal baseline tryptase. Diagnosis is clinical, supported by mediator testing when it can be collected properly.

Is MCAS the same as histamine intolerance? No. Histamine intolerance reflects limited capacity to break down dietary histamine. MCAS is excessive release of many mediators. They frequently coexist, and treating both matters.

Do I need a lifelong low-histamine diet? Almost never, and pursuing one usually backfires. Restriction is a diagnostic and stabilization tool with a defined endpoint.

Can MCAS start after a virus? Yes. Post-infectious onset is well recognized, including after COVID-19, and often responds to the same stepwise approach.

How long before I know if treatment works? Antihistamine response is often apparent within two weeks. Stabilizers such as cromolyn need 6–12 weeks at an adequate dose before you judge them.

Getting Evaluated in NYC

If you have been through multiple specialists without an explanation for multi-system, trigger-driven symptoms, a structured mast cell evaluation is a reasonable next step. Dr. Dhaliwal sees patients in New York City and Salt Lake City, and integrates mast cell care with gut, hormone, autonomic, and regenerative treatment rather than treating each in isolation.

Book a consultation to review your history, testing, and a sequenced plan. You can also browse more on our blog or read about our approach.

---

Medical disclaimer: This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Mast cell activation syndrome requires individualized evaluation by a qualified physician, and several conditions closely mimic it. Do not start, stop, or change any medication or supplement without consulting your own clinician. If you experience symptoms of anaphylaxis — throat swelling, difficulty breathing, collapse — use epinephrine if prescribed and call 911 immediately.